ICS 2018: Urodynamic Stratification of Elderly Male Patients with Symptoms of Lower Urinary Tract Dysfunction: A Medical Specialists Grading and Staging of Disease

Philadelphia, PA (UroToday.com)  This session was moderated by Dr. Abrams, Dr. Gray, and Dr. McKinney.  Dr. Roiser presented an abstract on the UDS stratification in an elderly patient with LUTS. He went through the history and development of bladder outflow obstruction (BOO) grading based on UDS.

 is (ICS) standardized since 1997.) A clinical disease-specific nomogram is available to graphically display the pressure-flow relation.(2) This nomogram has been the basis for the ICS bladder outflow obstruction index (BOOI) and the ICS bladder contraction index (BCI). Elderly men with symptoms of lower urinary tract dysfunction (LUTS) have a significant chance that BOO is the cause. The growing prostate creates a slowly increasing resistance to the outflow tract, however, the resistance is not exactly proportional to the size of the prostate. On the other hand, a reduced flowrate may be caused by an underactive detrusor contraction. Both, flowrate (including PVR) and prostate size have an intermediate sensitivity and specificity with regard to the gold standard diagnosis. Guidelines support the management of LUTS on the basis of subjective expression and interpretation of symptoms plus flowrate maximum. Urodynamic testing is avoided in practice for many reasons and therefore maximum free flowrate is commonly used as the predominant (or only) objective test to grade the dysfunction responsible for the symptoms. We have therefore precisely studied flowrate in comparison with pressure flow outcome and have explored the consequences of diagnosis, on the basis of flowrate, or on urodynamics in nearly 2500 men.

Dr. Rosier had analyzed 2459 men >45 year with LUTS. All these -consecutive- patients were referred and had bothering symptoms. A urodynamic pressure flow test was done after ICS standard cystometry and in the patients preferred position. He has not excluded measurements, but patients without free flow before urodynamics were not included. Pressure flow result is shown per linearized passive urethral resistance class (LinPURR) and per nomogram contraction class. Free flow study was produced by all included patients just before the cystometry. Not always representative (as reported by the patient), nevertheless all results (with volume over 50mL) were included, to present the most naturalistic set of patients.

The graphs show (upper left) that for the total group of patients absence of BOO (combining OBS grade 0 1 and 2, vertical) with reduced contractility (combining very weak and weak contraction classes) was present in 37.7% of patients. In 34% of all patients, the contraction was normal or strong, without BOO (< OBS 3). BOO was confirmed in 28.7% of all these men combined with weak contractility in 4.7%. BOO was severe (grade OBS 5 or 6) in 3.3% of the patients. If flowrate was <10mL/s (in 457 men), again, 38.7% of men had no BOO and weak contraction, and 22% of these men had no BOO and normal contraction. 39.2% of these men had BOO; 5.8% in combination with weak contraction and for 6.8% the BOO was graded severe. In the group with flowrate >14mL/s (338 men), only 3 had a severe grade of BOO (1%) and 85.6% of these men had no BOO and 56.2% had normal contractility.

UroToday ICS2018 4. Urodynamic Stratification of Elderly Male Patients with Symptoms of Lower Urinary Tract Dysfunction

Flowrate is reduced in patients with BOO. Patients with a flowrate above 14mL/s rarely (14.4%) have BOO, which is virtually never high graded (1%). If the flowrate is <14mL/s roughly 35% of the patients have BOO and underactive detrusor. Of all patients with symptoms and flowrate, 28,7% has BOO grade 3 or higher. If BOO grade >3 is taken as the threshold to advise surgical des-obstruction, only 3,3% of all patients would be advised positively for this. 71% of all patients would profit from conservative measures (with low intensity follow up) because no BOO is responsible for their symptoms, however,>50% of these men without BOO has underactive detrusor, for whom no specific treatment is available. A proportion of men will have storage dysfunction (uncovered by the urodynamic testing), this is however not included in this analysis (that mimics the usual guideline practice advise). 25,5% of all men could safely continue or start with specific medical treatment based on a moderate grade of BOO.

Conservative or medical management is usually safe and effective in elderly men with LUTD. However, many men want reconfirmation of this when the treatment has been based on symptoms only. They persist in anxiety and bother about their symptoms and ask for a referral. Objective urodynamic stratification is the golden standard tool to diagnose the dysfunction and urologists are able to use this. ICS has been instrumental to develop the tools and techniques. As stated above: Many men can be reassured and may continue with conservative measures of medication on the basis of urodynamic grading of the dysfunction. Guidelines advise to consider des-obstruction for patients with persisting symptoms and reduced flowrate on the basis of indirect evidence, urodynamics would confirm this individually in around 30% of patients based on an objective measure.

Take home message: Urodynamic objective grading and staging of the dysfunction, as developed by ICS, is very helpful in medical specialists perspective. Including urodynamic staging and grading of dysfunction in elderly male patients as a sine qua non in guidelines for medical specialist management would reduce unnecessary (potentially >60%) surgery in elderly men, referred with bothersome signs and symptoms of lower urinary tract dysfunction. 

Presented by: DR. P.F.W.M. Peter Rosier, Associate Professor, Department of Urology,University Medical Center Utrecht

Written by: Bilal Farhan, MD; Clinical Instructor, Female Pelvic Medicine and Reconstructive Surgery, University of California, Irvine Medical Center, Twitter: @Bilalfarhan79 at the 2018 ICS International Continence Society Meeting - August 28 - 31, 2018 – Philadelphia, PA USA